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The aim of this study was to determine the associations between hysterectomy, bilateral salpingo-
oophorectomy (BSO), and incidence of diabetes in postmenopausal women participating in the Women’s Health
Initiative (WHI), a series of trials conducted in the United States, during the period 1993–1998. A total of 67,130
postmenopausal women aged 50–79 years were followed for a mean of 13.4 years. Among them, 7,430 cases of
diabetes were diagnosed. Multivariable Cox proportional hazards models were used to assess the association be-
tween hysterectomy/oophorectomy status and diabetes incidence. Compared with women without hysterectomy,
women with hysterectomy had a significantly higher risk of diabetes (hazard ratio = 1.13, 95% confidence interval:
1.06, 1.21). The increased risk of diabetes was similar for women with hysterectomy only and for women with hys-
terectomy with concomitant BSO. Compared with hysterectomy alone, hysterectomy with BSO was not asso-
ciated with additional risk of diabetes after stratification by age at hysterectomy and hormone therapy status. In
our large, prospective study, we observed that hysterectomy, regardless of oophorectomy status, was associated
with increased risk of diabetes among postmenopausal women. However, our data did not support the hypothesis
that early loss of ovarian estrogens is a risk factor for type 2 diabetes. The modest increased risk of diabetes asso-
ciated with hysterectomy may be due to residual confounding, such as the reasons for hysterectomy.
diabetes; hysterectomy; oophorectomy; postmenopausal women
Abbreviations: BSO, bilateral salpingo-oophorectomy; CI, confidence interval; HR, hazard ratio; WHI, Women’s Health Initiative.
Hysterectomy is the second most common surgery among
women in the United States, and approximately 600,000 hys-
terectomies are performed in the United States annually (1).
Almost 90% of surgeries are for benign gynecologic condi-
tions, including symptomatic uterine fibroids or abnormal
uterine bleeding (2, 3). Approximately 44% of women have
concomitant bilateral salpingo-oophorectomy (BSO) at the
time of hysterectomy in order to prevent the subsequent devel-
opment of ovarian cancer, treat medical conditions, or prevent
the need for future adnexal surgery (4). In premenopausal
women, BSO induces menopause, but hormonal effects may
also be present in postmenopausal women (5, 6). In addition,
hysterectomy without BSO has been associated with a shorter
time to menopause (7) and has been found to have similar, but
less dramatic, hormonal changes as BSO (5, 8, 9). Increased
knowledge about the long-term effects of hysterectomy and
BSO on women’s health will improve medical decision-
making for women and their providers (10).
BSO before age 50 years is significantly associated with
death from all causes (11). Some have attributed this to a
higher risk of cardiovascular disease (12). It has been postu-
lated that women who undergo early BSO may subsequently
experience a higher risk of type 2 diabetes mellitus (hereafter
referred to as diabetes) compared with women who do not
undergo oophorectomy (13). According to Mauvais-Jarvis
et al. (14), ovarian hormones regulate both insulin secretion
and survival of pancreatic beta cells. In animal studies,
an absence of female sex hormones after BSO leads to de-
creased whole-body insulin-mediated glucose uptake (15,
16). Oophorectomy worsens glucose tolerance and insulin
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resistance in mice (17). Furthermore, several randomized clin-
ical trials have indicated that exogenous menopausal hormone
therapy (either estrogen alone or estrogen plus progestin) re-
duces the risk of diabetes (18–20). Thus, we hypothesized that
early BSO would be associated with an increased risk of dia-
betes and that hysterectomy without BSO might be associated
with an intermediate risk compared with undergoing neither
BSO nor hysterectomy.
Epidemiologic studies investigating the associations
between hysterectomy, BSO, and diabetes incidence are
sparse. Appiah et al. (21), using data from 2,597 postmeno-
pausal women enrolled in the National Health and Nutrition
Examination Survey I Epidemiologic Follow-up Study,
reported that hysterectomy with BSO was significantly asso-
ciated with diabetes risk (hazard ratio (HR) = 1.57, 95%
confidence interval (CI): 1.03, 2.41), while hysterectomy
alone was associated with a nonsignificantly increased risk of
diabetes (HR = 1.38, 95% CI: 0.94, 2.04). In another small,
prospective study (only 33 women with BSO), Lejsková
et al. (22) found that women with BSO had a significant
increase in fasting glycemia compared with women with
natural menopause. In a third study, a secondary analysis of a
randomized controlled trial among glucose intolerant adults,
Kim et al. (23) reported no association between diabetes risk
and bilateral oophorectomy. In that study, analysis of the sub-
group that was randomized to a lifestyle intervention indi-
cated that diabetes risk was lower among women with BSO
compared with premenopausal women (23). However the
population was women at high risk of diabetes, and investiga-
tors were unable to assess the effects of hormone use due to
the lack of diabetes cases.
The purpose of this study was to use a large prospective
data set (the Women’s Health Initiative (WHI)) to examine
the associations between hysterectomy, BSO, and incidence
of diabetes while adjusting for important confounders. We
also tested the hypothesis that early loss of ovarian estrogens
is a risk factor for diabetes by comparing diabetes risk among
women who had hysterectomy with BSO with the risk
among women who underwent hysterectomy only, stratified
by age at hysterectomy and hormone therapy status.
METHODS
Women’s Health Initiative
The WHI was designed to address the major causes of
morbidity and mortality in postmenopausal women (24). It
includes both multicenter clinical trials and an observational
study. Details of the scientific rationale, eligibility require-
ments, and baseline characteristics of the participants in the
WHI have been published elsewhere (25–29). Briefly, a total
of 161,808 women aged 50 to 79 years were recruited at 40
clinical centers throughout the United States between Sep-
tember 1, 1993, and December 31, 1998. The current study
uses the WHI Observational Study data. Participants in the
Observational Study included 93,676 women who were
screened for the clinical trial but were ineligible or unwilling
to participate or who were recruited through a direct invita-
tion for the Observational Study. The study was overseen by
institutional review boards at all 40 clinical centers and at the
coordinating center as well as by a study-wide data and
safety monitoring board. All WHI participants gave signed
informed consent and were followed prospectively.
The following participants were excluded from the Obser-
vational Study cohort of 93,676 for this analysis: 10,197
women who had a history of cancer (except nonmelanoma
skin cancer) at baseline; 549 who joined but provided no
follow-up information; 4,517 who had prevalent diabetes
(defined as a positive answer to the question, “Did a doctor
ever say that you had sugar diabetes or high blood sugar
when you were not pregnant?”) at baseline; 1,667 women
with missing data on hysterectomy or oophorectomy; 6,109
women who had unilateral or partial oophorectomy; and
3,507 women with missing data on other covariates. After
exclusions, 67,130 women remained for further analysis.
WHI cohort follow-up
The WHI Observational Study enrollment period was
1994 through 1998. Observational Study participants were
followed for 6–10 years in the main study depending on when
they enrolled in the study. WHI extension studies continued
to follow consenting participants, the first for an additional
5 years (2005–2010) and the second for another 5 years
(2010–2015). Consent rates to the WHI extension studies
were 82.4% for clinical trials and 72.9% for the Observa-
tional Study for the first extension (2005–2010) and 85.2%
for clinical trials and 88.2% for the Observational Study
for the second extension (2010–2015). Annual updates on
health outcomes were collected by mail from the participants.
The annual follow-up response rate was over 94% each year.
The reasons that participants were censored included death,
nonconsent to the extensions, or end of follow-up. The max-
imum length of follow-up was 20 years.
Measurements of exposure and outcome
Exposures. Hysterectomy status at baseline was deter-
mined via self-report at enrollment by asking the following
question: “Did you ever have a hysterectomy? (This is a sur-
gery to take out your uterus or womb.)” The responses to
this question were categorized as no or yes. Oophorectomy
status at baseline was determined by asking “Have you ever
had an operation to remove one or both of your ovaries?”
The responses to this question were categorized as no; yes,
one was taken out; yes, both were taken out; yes, part of an
ovary was taken out; yes, unknown number taken out; and
don’t know. The validities of self-reported hysterectomy and
BSO experience have been confirmed with a sensitivity of
91% and positive predictive value of 97% for hysterectomy
status and sensitivity of 64% and positive predictive value of
100% for BSO (30). Age at hysterectomy and age at BSO
were collected at baseline. WHI also collected the hysterec-
tomy status and the date of the operation during follow-up.
Oophorectomy status was not collected during follow-up.
Outcome. The primary outcome was incidence of dia-
betes during follow-up. This was defined via self-report by a
positive report of a new diagnosis of diabetes treated with in-
sulin or oral medications during follow-up. Self-reported dia-
betes in the WHI has been found to be valid based on
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medication inventories, fasting glucose levels, and medical re-
cord review (31, 32).
Covariates. In the multivariable models, we considered
potential confounders, including age at enrollment (continu-
ous), race/ethnicity (American Indian or Alaska Native, Asian
or Pacific Islander, black or African American, Hispanic/La-
tino, non-Hispanic white, and other), education (high school
or less, some college/technical training, college or some
graduate work, and master’s degree or higher), body mass
index (weight divided by the square of height (kg/m2), con-
tinuous), smoking (never smoker, former smoker, current
smoker), alcohol intake (no alcohol consumption, past alcohol
consumption, current and <7 alcoholic beverages/week, cur-
rent and ≥7 alcoholic beverages/week), physical activity
(metabolic equivalent (MET) hours/week: <5, 5–<10, 10–
<20, 20–<30, ≥30), history of hormone therapy use (none,
estrogen alone, estrogen and progestin, mixed), age at first
birth (never had term pregnancy, <20 years, 20–<30 years,
≥30 years), age at menarche (<12 years, 12–14 years, ≥15
years), parity (never had term pregnancy, 1–2, ≥3), family
history of diabetes (no, yes), waist circumference (centi-
meters), hypertension (yes, no), and high serum cholesterol
requiring medication (yes, no).
Statistical analysis
Our primary analysis focused on the association between
hysterectomy/oophorectomy status at baseline and risk of
diabetes, because the WHI did not collect information on
oophorectomy status during follow-up. Hysterectomy/
oophorectomy status was divided into 4 categories: no hys-
terectomy or oophorectomy, no hysterectomy but BSO, hys-
terectomy alone, and hysterectomy with BSO.
Baseline characteristics were described using percentages
for categorical variables and mean values (with standard
deviations) for quantitative variables. Comparisons between
the 4 groups (according to hysterectomy/oophorectomy sta-
tus) were made using the χ2 test for categorical variables
and analysis-of-variance test for quantitative variables.
Multivariable Cox proportional hazards models were used
to assess the association between hysterectomy/oophorectomy
status and diabetes incidence. In all multivariable models, po-
tential confounders included variables listed in Table 1. To
further test the hypothesis of whether early loss of ovarian es-
trogens is a risk factor for diabetes, we examined the associ-
ation between hysterectomy with concomitant BSO and risk
of diabetes according to age at hysterectomy (<45 years or
≥45 years) and hormone therapy status (never use, ever use),
using women with hysterectomy alone as the reference group.
In this way, we could further control for the confounding
related to indications for hysterectomy. We also analyzed
exposure (hysterectomy status) as a time-varying variable
using time-dependent covariate Cox models.
We used SAS, version 9.4 (SAS Institute, Inc., Cary,
North Carolina), for all analyses.
RESULTS
Among 67,130 women, 24,352 women (36.3%) had had
hysterectomy at baseline. Among these, 13,761 (56.5%) had
had concomitant BSO. As of September, 30, 2015, over a
mean of 13.4 years of follow-up, 7,430 women (10.5%)
developed diabetes. Among women who had not had hyster-
ectomy at baseline, 4,387 (10.32%) developed diabetes,
compared with 3,043 (12.5%) of women who had had hys-
terectomy at baseline and 1,731 (12.6%) of women who had
had hysterectomy and BSO at baseline.
Baseline characteristics by hysterectomy and oophorec-
tomy status at enrollment are shown in Table 1. Compared
with women who did have hysterectomy or oophorectomy,
women who had hysterectomy only or with concomitant
BSO were more likely to be older, to be nonwhite (non-His-
panic), to be less educated, and to have higher body mass in-
dex. They were less physically active and were more likely to
be a nonsmoker, to be a nondrinker of alcohol, to report a
family history of diabetes, to have history of hormone use of
estrogen alone, to have a longer duration of hormone therapy
use, to have had menarche at a younger age, and to have been
younger at their first childbirth. Compared with women had
not had hysterectomy or oophorectomy, women who had not
had hysterectomy but had had BSO had similar patterns as
women with hysterectomy except for the following character-
istics: they were more educated, more likely to be current
smokers, and more likely to be nulliparous. Compared with
women who had had hysterectomy alone, women with BSO
regardless of hysterectomy were more likely to have had low
parity and have had surgery at early age (Table 1).
In age-adjusted models, hysterectomy was associated with
an increased risk of diabetes regardless of BSO status. The
association between hysterectomy and risk of diabetes was at-
tenuated but remained significant after adjusting for all potential
confounders. The increased risk of diabetes was similar for
women who had undergone hysterectomy only and for women
who had had hysterectomy plus BSO. Women who had not had
hysterectomy but had had BSO had no significant increased risk
of diabetes compared with women who had not had hyster-
ectomy or oophorectomy (Table 2). When stratified by age
at oophorectomy (<45 years or ≥45 years), no significantly
increased risk of diabetes was observed in women with no
hysterectomy but with BSO in either stratum.
When analyzed according age at time of hysterectomy
and hormone therapy use, compared with women who had
had hysterectomy alone, women who had had hysterectomy
plus BSO did not show an additional risk of diabetes
(Table 3). The results were similar when stratified by age at
time of hysterectomy at 50 years. We also performed analy-
sis for hysterectomy and age at hysterectomy according to
hormone therapy use by using no hysterectomy or BSO as
the referent. Hazard ratios were similar and approximately
1.1–1.4 (Appendix Table 1).
In addition, we did not observe that the age of women
at time of hysterectomy was associated with diabetes diag-
nosis. When hysterectomy status was analyzed as a time-
varying variable using time-dependent covariate Cox
models, a similarly increased risk of diabetes was observed
in women who had had hysterectomy compared with women
who had not had hysterectomy after adjusting for potential
risk factors (HR = 1.12, 95% CI: 1.06, 1.18). Finally, we
performed several sensitivity analyses. First, we performed
an analysis for women who had had partial oophorectomy.
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Table 1. Characteristics of Study Participants According to Hysterectomy/Oophorectomy Status Among 67,130 Participants in the Women’s
Health Initiative Observational Study, United States, 1993–1998
Characteristic
No Hysterectomy/
Oophorectomy
(n = 42,535)
No Hysterectomy
But Bilateral
Oophorectomy
(n = 243)
Hysterectomy Only
(n = 10,591)
Hysterectomy and
Bilateral
Oophorectomy
(n = 13,761)
% Mean (SD) % Mean (SD) % Mean (SD) % Mean (SD)
Age at baseline, years 63.1 (7.3) 64.2 (7.2) 63.4 (7.4) 63.7 (7.3)
Race/ethnicity
American Indian or Alaskan Native 0.3 0.8 0.5 0.4
Asian or Pacific Islander 3.4 3.3 1.9 2.7
Black or African American 5.4 5.8 8.3 8.2
Hispanic/Latino 3.3 2.5 4.7 3.1
Non-Hispanic white 86.2 85.2 83.4 84.2
Other 1.4 2.5 1.3 1.4
College graduate or more education 21.6 24.3 14.6 17.0
Body mass indexa 26.6 (5.6) 27.0 (5.5) 27.3 (5.5) 27.3 (5.8)
Physical activity, MET-hours/week 14.6 (14.7) 14.2 (14.9) 13.4 (14.2) 13.2 (13.9)
Smoking status
Never smoker 50.7 49.0 52.8 51.6
Former smoker 43.3 42.8 41.1 42.8
Current smoker 6.1 8.2 6.2 5.6
Alcohol intake
No alcohol 10.0 12.4 12.0 11.1
Past alcohol use 15.8 18.1 19.7 19.0
<7 alcoholic beverages/week 60.1 57.6 56.6 58.1
≥7 alcoholic beverages/week 14.1 11.9 11.8 11.8
Family history of diabetes, yes 28.2 31.7 32.0 32.0
History of hormone therapy use
None 49.5 37.9 26.5 15.4
Estrogen alone 6.7 20.2 65.0 71.6
Estrogen and progestin 38.5 29.2 2.4 2.8
Mixed 5.4 12.8 6.2 10.3
Duration of hormone therapy, years 6.6 (5.9) 8.6 (8.4) 11.3 (9.0) 13.4 (9.2)
Age at menarche, years
<12 20.8 24.7 22.7 23.4
12–14 69.5 65.0 67.7 67.6
≥15 9.7 10.3 9.7 9.0
Age at first birth, yearsb
Never had term pregnancy 13.4 22.6 6.5 13.6
<20 8.4 7.8 16.1 12.6
20 to <30 60.0 51.4 63.4 59.3
≥30 9.1 9.5 4.8 5.8
Parity
Never had term pregnancy 13.4 22.6 6.5 13.6
1–2 35.7 40.7 32.6 37.6
≥3 50.8 36.6 60.9 48.8
Table continues
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Compared with women who had had neither hysterectomy
nor oophorectomy, women who had not had hysterectomy
but had had partial oophorectomy had no increased risk of
diabetes (HR = 0.92, 95% CI: 0.79, 1.07); women who had
had hysterectomy and had had partial oophorectomy had a
similarly increased risk of diabetes (HR = 1.17, 95% CI:
1.06, 1.29) as women who had had hysterectomy alone
(HR = 1.14, 98% CI: 1.06, 1.22) or women who had had
hysterectomy plus BSO (HR = 1.16, 95%CI: 1.08, 1.24).
Second, we further adjusted for age at menopause, and re-
sults were similar. Third, analyses according to race/ethnicity
showed that the association between hysterectomy and risk
of diabetes was consistent across racial/ethnic groups.
DISCUSSION
In this large, prospective study of postmenopausal women,
we observed that hysterectomy status regardless of oophorec-
tomy status was associated with increased risk of diabetes.
Compared with women who have undergone hysterectomy
alone, concomitant BSO did not impart additional risk of dia-
betes regardless of the age at hysterectomy or the hormone
therapy status.
A few epidemiologic studies have examined the associa-
tions between hysterectomy, BSO, and risk of diabetes, and
they have yielded inconsistent results (21–23). Kim et al.
(23) reported no increased risk of diabetes associated with
Table 1. Continued
Characteristic
No Hysterectomy/
Oophorectomy
(n = 42,535)
No Hysterectomy
But Bilateral
Oophorectomy
(n = 243)
Hysterectomy Only
(n = 10,591)
Hysterectomy and
Bilateral
Oophorectomy
(n = 13,761)
% Mean (SD) % Mean (SD) % Mean (SD) % Mean (SD)
Age at hysterectomy/oophorectomy, years
<40 63.8 17.6 32.5
40 to <50 12.4 42.0 46.3
≥50 21.8 40.0 21.0
Abbreviations: MET, metabolic equivalent of task; SD, standard deviation.
a Body mass index was calculated as weight (kg)/height (m)2.
b The numbers may not sum to the total because of missing values.
Table 2. Hazard Ratios for the Association Between Hysterectomy/Oophorectomy and Risk of Diabetes Among 67,130 Participants in the
Women’s Health Initiative Observational Study, United States, 1993–1998
Surgical Status
No. of
Diabetes
Cases
Person-Years
Crude Incidence Rates
(per 1,000
Person-years)
Age-Adjusted
Adjusted for Age,
Prior Hormone
Use, and BMI
Multivariable-
Adjusteda
HR 95% CI HR 95% CI HR 95% CI
Hysterectomy
No 4,387 581,257 7.55 1 Referent 1 Referent 1 Referent
Yes 3,043 319,805 9.52 1.27 1.21, 1.33 1.25 1.17, 1.33 1.13 1.06, 1.21
Hysterectomy/oophorectomy
None 4,360 578,146 7.54 1 Referent 1 Referent 1 Referent
No hysterectomy but bilateral
oophorectomy
27 3,111 8.68 1.19 0.81, 1.74 1.20 0.82, 1.75 1.02 0.70, 1.49
Hysterectomy without
oophorectomy
1,312 138,920 9.44 1.27 1.19, 1.35 1.25 1.16, 1.35 1.12 1.04, 1.21
Hysterectomy with bilateral
oophorectomy
1,731 180,884 9.57 1.28 1.21, 1.35 1.26 1.17, 1.35 1.14 1.06, 1.23
Abbreviations: CI, confidence interval; HR, hazard ratio.
a In the multivariable-adjustment models, we adjusted for potential confounders, including age (continuous) at enrollment, race/ethnicity (American
Indian or Alaska Native, Asian or Pacific Islander, black or African American, Hispanic/Latino, non-Hispanic white, and other), body mass index (con-
tinuous), education (high school or less, some college/technical training, college or some graduate work, and master’s degree or higher), smoking
(never, former, current), alcohol intake (no alcohol, past alcohol consumption, current and <7 alcoholic beverages/week, current and ≥7 alcoholic
beverages/week), physical activity (metabolic equivalent hours/week: <5, 5–<10, 10–<20, 20–<30, ≥30), family history of diabetes (no, yes), age at
first birth (never had term pregnancy, <20 years, 20–<30 years, ≥30 years), age at menarche (<12 years, 12–14 years, ≥15 years), parity (never had
term pregnancy, 1–2,≥3), waist circumference (continuous), hypertension (yes, no), and high serum cholesterol requiring medication (yes, no).
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bilateral oophorectomy overall or a reduced risk associated with
bilateral oophorectomy in a subgroup compared with premeno-
pausal women. Two studies (21, 22) observed an increased risk
of diabetes in women who underwent hysterectomy concomi-
tant with BSO, which is in line with our finding. However,
Lejsková et al. (22) did not examine the association between
hysterectomy alone and risk of diabetes, and Appiah et al.
(21) observed a nonsignificantly increased risk of diabetes as-
sociated with hysterectomy alone (HR = 1.38, 95% CI: 0.94,
2.04). In fact, the magnitude of the association found by Ap-
piah et al. is greater than our adjusted point estimate of 1.15
(95% CI: 1.07, 1.24) for hysterectomy only. Thus, we think
that the nonsignificant finding in Appiah et al. may be due to
low statistical power to detect a modest association with
hysterectomy.
To our knowledge, our study is the first epidemiologic
study to directly compare risk of diabetes associated with
BSO to that associated with hysterectomy alone according
to age at hysterectomy and hormone therapy status. We
considered age at hysterectomy for 2 reasons. First, the in-
dications and reasons for younger women to undergo hys-
terectomy might differ from those of older women who
were in perimenopausal or postmenopausal stages. Second,
the impact of hormone changes following hysterectomy
may be different on younger women than on older women,
because women having surgery before the typical age at
natural menopause may experience more substantial
changes in hormone levels than women who are many
years past menopause. We observed that among postmeno-
pausal women (compared with women who underwent
hysterectomy), concomitant BSO did not impart additional
risk of diabetes regardless of the age at hysterectomy and
hormone therapy status. Using hysterectomy alone as a
reference group helped control for the confounding related
to indications for hysterectomy. The results were also
supported by the finding that women with BSO alone had
no increased risk of diabetes compared with women who
had had neither hysterectomy nor BSO. Our findings are
consistent with those of a WHI study in which Jacoby et al. (3)
reported that BSO was not associated with risks of cardiovas-
cular disease, hip fracture, cancer, or total mortality when
compared with hysterectomy and ovarian conservation.
Women who have had BSO represent a unique popula-
tion because they have a sudden dramatic decrease in both
their androgen and estrogen production (5, 33). Experimen-
tal data demonstrate a protective role for estrogens in glu-
cose metabolism (34, 35). Hormone therapy has also been
associated with a lower incidence of diabetes in postmeno-
pausal women (18–20). We were able to control for the use
of hormone therapy in our study; however, the null findings
from our data did not support the hypothesis that early loss
of ovarian estrogen is a risk factor for diabetes. This might
be because BSO reduces both androgen and estrogen pro-
duction (5, 33), and, while deficiency of estrogen may be
associated with increased risk of diabetes, reduced androgen
may also lead to lower risk of diabetes (36, 37). Therefore,
the overall positive and negative effects of BSO on risk of
diabetes may cancel out. Another explanation may be that
circulating estrone and estradiol levels are derived primarily
from peripheral aromatization of androstenedione and testos-
terone among postmenopausal women. Studies have shown
that oophorectomy does not seem to influence peripheral
estrogen production in older women (38). Therefore, the ab-
solute difference in hormone levels between women who
Table 3. Hazard Ratios for Diabetes in WomenWith Hysterectomy and Bilateral Oophorectomy ComparedWith WomenWith Hysterectomy
Alone, According to Age at Hysterectomy and Hormone Therapy Status, Women’s Health Initiative Observational Study, United States,
1993–1998a
Hormone Therapy and
Surgical Status
Hysterectomy Before Age 45 Hysterectomy After Age 45
No. of
Cases
Person-
Years
Crude Incidence
Rates (per 1,000
Person-years)
HR 95% CI No. ofCases
Person-
Years
Crude Incidence
Rates (per 1,000
Person-years)
HR 95% CI
Women who never used
hormone therapy
Hysterectomy alone 265 22,078 12.00 1 Referent 129 12,034 10.72 1 Referent
Hysterectomy with BSO 126 10,026 12.57 1.00 0.80, 1.24 166 15,002 11.07 1.01 0.80, 1.29
Women who ever used
hormone therapy
Hysterectomy alone 620 68,924 9.00 1 Referent 292 35,367 8.26 1 Referent
Hysterectomy with BSO 610 62,208 9.81 1.01 0.90, 1.13 825 93,218 8.85 0.99 0.86, 1.14
Abbreviations: BSO, bilateral oophorectomy; CI, confidence interval; HR, hazard ratio.
a In the multivariable-adjustment models, we adjusted for potential confounders, including age (continuous) at enrollment, race/ethnicity
(American Indian or Alaska Native, Asian or Pacific Islander, black or African American, Hispanic/Latino, non-Hispanic white, and other), body
mass index (continuous), education (high school or less, some college/technical training, college or some graduate work, and master’s degree or
higher), smoking (never, former, current), alcohol intake (no alcohol, past alcohol consumption, current and <7 alcoholic beverages/week, current
and ≥7 alcoholic beverages/week), physical activity (metabolic equivalent hours/week: <5, 5–<10, 10–<20, 20–<30, ≥30), family history of dia-
betes (no, yes), age at first birth (never had term pregnancy, <20 years, 20–<30 years, ≥30 years), age at menarche (<12 years, 12–14 years,
≥15 years), parity (never had term pregnancy, 1–2, ≥3), waist circumference (continuous), hypertension (yes, no), and high serum cholesterol
requiring medication (yes, no).
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undergo hysterectomy with or without BSO may not be
sufficient to demonstrate a significant difference on risk of
diabetes in older women. In fact, 2 studies observed no dif-
ference in estradiol or estrone levels associated with BSO
in postmenopausal women and no differential influence of
timing of oophorectomy (e.g., before or after natural meno-
pause) on estrogen levels (5, 6).
The modestly increased risk of diabetes associated with
hysterectomy that we observed could have several explana-
tions. First, the increased risk might be due to a true in-
creased risk from surgery leading to lower estrogen levels.
After hysterectomy without BSO, patients experience shor-
ter time to ovarian failure and menopausal symptoms (8, 9).
Farquhar et al. (7) demonstrated that the onset of menopause
in women who underwent hysterectomy retaining both ova-
ries was nearly 4 years earlier than for women with intact
uteri. Early menopause may lead to a shift toward androgen
predominance, including a decrease in sex hormone–bind-
ing globulin levels. Increased androgenicity has been linked
to glucose intolerance (39).
A second explanation for the modest increased risk of dia-
betes associated with hysterectomy may be residual con-
founding due to the indication for hysterectomy. For
example, obesity has been suggested as a major risk factor
for abnormal uterine bleeding (40) and fibroids (41), which
are leading indications for hysterectomy. It is also a risk fac-
tor for diabetes. Although we were able to adjust for body
mass index, there may be residual unmeasured confounding
factors that predispose women to surgery and also to dia-
betes. If the association between hysterectomy and risk of
diabetes truly operates via lower estrogen or early meno-
pause, then we would have expected to observe a higher risk
of diabetes in women who underwent BSO.
Another explanation for the modest increased risk of dia-
betes associated with hysterectomy might be surveillance
bias. For example, women who undergo hysterectomy and/
or BSO might be more likely to be under a doctor’s care or
might see medical professionals more frequently during
follow-up, thereby making it more likely that they would be
screened for diabetes and subsequently diagnosed with dia-
betes. There are no data about the rates of diabetes screening
in this population; however, we compared the average num-
ber of cholesterol tests (a surrogate variable for receipt of
medical care) over the follow-up period by hysterectomy or
oophorectomy status and did not observe appreciable differ-
ences in the numbers, suggesting that our findings are un-
likely to be due to surveillance bias.
Strengths of our study include the prospective design
with detail about potential confounders, the large sample
size and long-term follow-up, and the ability to observe the
association across several racial/ethnic groups. However,
several limitations deserve mention. First, although other
studies have reported reasonable validity for self-report of
hysterectomy, hysterectomy and oophorectomy status were
self-reported rather than verified from records. The nondif-
ferential misclassification of exposures would tend to at-
tenuate the associations for extreme exposure levels.
However, if the degree of misclassification between hyster-
ectomy alone and hysterectomy plus BSO were very high, it
is possible that biases due to the misclassification could dis-
tort an exposure-response relationship if it exists (none, hys-
terectomy alone, hysterectomy plus BSO). Second, we are
unable to determine whether women who reported prior hys-
terectomy and BSO underwent these surgeries concomi-
tantly or at different times. However, most women likely
underwent BSO at the time of hysterectomy. Third, our ana-
lyses may also be affected by survival bias, because WHI
participants began follow-up many years after they under-
went hysterectomy. In our study, we required all participants
to be free of diabetes at the start of our follow-up period;
thus, women who underwent hysterectomy and developed
diabetes earlier than the start of the follow-up period were
excluded. Therefore, the relative risk of diabetes associated
with hysterectomy may be underestimated. Fourth, we do
not know the risk-factor status of participating women be-
fore hysterectomy or the reason for the surgery. Finally, the
outcome measure is self-reported diagnosis of diabetes and/
or diabetes medication use, which may lead to some nondif-
ferential misclassification.
In conclusion, our large, prospective study observed that
hysterectomy status regardless of oophorectomy status was
associated with increased risk of diabetes among postmeno-
pausal women. However, our data did not support the hy-
pothesis that early loss of ovarian estrogens is a risk factor
for diabetes. The modest increased risk of diabetes asso-
ciated with hysterectomy may be due to residual confound-
ing or indications for hysterectomy.
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Appendix Table 1. Hazard Ratios for Diabetes in WomenWith Hysterectomy According to Age at Hysterectomy
and Hormone Therapy Status, Women’s Health Initiative Observational Study, United States, 1993–1998a
Hysterectomy
Never Used Hormone Therapy Ever Used Hormone Therapy
No. of Cases HR 95% CI No. of Cases HR 95% CI
No 2,337 1 2,050 1
Yes 689 1.12 1.03, 1.22 2,354 1.13 1.06, 1.20
Before age 45 years 391 1.12 1.01, 1.25 1,230 1.11 1.04, 1.20
After age 45 years 295 1.12 0.99, 1.27 1,117 1.14 1.06, 1.23
Abbreviations: CI, confidence interval; HR, hazard ratio.
a In the multivariable-adjustment models, we adjusted for potential confounders, including age (continuous) at
enrollment, race/ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, black or African American, His-
panic/Latino, non-Hispanic white, and other), body mass index (continuous), education (high school or less, some col-
lege/technical training, college or some graduate work, and master’s degree or higher), smoking (never, former,
current), alcohol intake (no alcohol, past alcohol consumption, current and <7 alcoholic beverages/week, current and
≥7 alcoholic beverages/week), physical activity (metabolic equivalent hours/week: <5, 5–<10, 10–<20, 20–<30,
≥30), family history of diabetes (no, yes), age at first birth (never had term pregnancy, <20 years, 20–<30 years, ≥30
years), age at menarche (<12 years, 12–14 years, ≥15 years), parity (never had term pregnancy, 1–2, ≥3), waist cir-
cumference (continuous), hypertension (yes, no), and high serum cholesterol requiring medication (yes, no).
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